Study on Immune Response and Diagnostics for Mpox Infection and Vaccination Focus on Populations at Risk and Post-Exposure Assessment

What this Trial Is About

Researchers are investigating Mpox, a disease with rising cases in Central and East Africa, caused by two virus strains with different characteristics and spread patterns. The study aims to develop new immune tests to estimate how many people have been exposed to Mpox or vaccinated, helping to prioritize vaccine use in affected communities. This outbreak is considered a public health emergency due to increasing cases and deaths, especially with limited testing in some regions. Participants are grouped by their exposure status those at risk but without symptoms, those recovered from Mpox or vaccinated, and those with no known exposure. The study uses diagnostic tests including an Mpox-specific antibody ELISA and a dried blood spot lateral flow assay to detect immune responses. All participants undergo the same testing procedures to assess their exposure or immunity status. During the study visit, participants provide biological samples for testing and complete surveys about their views on outbreak studies, immune diagnostic tools, and vaccine logistics. Researchers will measure Mpox-specific antibodies and evaluate rapid test accuracy. The study will also gather perspectives from healthcare workers and the public to support future vaccine strategies. The total participation involves sampling and questionnaires conducted on the first day.

Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks